Core Viewpoint - The significant rise of Jiuyuan Gene (02566) in the Hong Kong biotech sector, with a price increase of over 218% from a low of 5.119 HKD to a peak of 16.29 HKD, driven by the anticipation of the market launch of its GLP-1 drug, JY29-2, in 2026 [1][20]. Company Overview - Jiuyuan Gene specializes in GLP-1 drugs and is preparing to submit a drug application for its biosimilar, Semaglutide, in the first half of 2026 [1][18]. - The company has entered into exclusive licensing agreements for Semaglutide with other domestic pharmaceutical companies, expanding its market reach in Latin America and the Middle East [18]. Market Dynamics - The biotech sector is experiencing a surge in interest, particularly in the GLP-1 drug market, which is projected to exceed 150 billion USD by 2030, indicating a strong growth potential [19]. - Recent reports from multiple brokerages express optimism about weight-loss concept stocks, highlighting the GLP-1 sector as a new capital favorite [19]. Investment Behavior - The stock price movements of Jiuyuan Gene reflect a classic investment strategy involving accumulation, consolidation, and subsequent price increases, characterized by significant volatility and strategic selling [1][9][20]. - The stock saw a massive public offering with a subscription rate of 675.83 times, leading to a high retail investor ownership and a lack of institutional support [2][3]. Trading Phases - The trading phases of Jiuyuan Gene include a "building position" phase characterized by high volatility, a "washing" phase to rebalance shares, and a "main rising wave" phase where the stock price surged dramatically [1][9][10]. - The stock experienced a significant drop of 26.62% during the initial accumulation phase, followed by a 30.04% increase in the first rally phase, indicating a controlled accumulation strategy by major investors [4][7]. Recent Performance - The stock's recent performance includes a notable rebound from 7.85 HKD to 10.58 HKD, followed by a second main rising wave that saw the price increase by 53.88% [13][15]. - The trading volume and price movements suggest a high level of control by major investors, with significant buying activity during price dips and strategic selling at peaks [10][12][20].
从建仓洗盘到二次拉升：九源基因（02566）资本操盘术与司美格鲁肽的千亿想象